Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
30000 participants
OBSERVATIONAL
2018-04-01
2030-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Improvement of Personalized Lung Cancer Care Through Digital Connection and Patient Participation (DigiNet)
NCT05818449
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
NCT02622581
Characteristics of Advanced LUNG CANCER at the tIme of Diagnosis in a Large Italian Cohor
NCT06076005
Giessen Pulmonary Hypertension in Lung Cancer Registry
NCT04467333
Prospective Epidemiological Study of Metastatic Non Small Cell Lung Cancer (NSCLC) in Latin America
NCT04227457
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
observational, non-interventional
observational, non-interventional
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed, locally advanced or metastatic NSCLC (Union for International Cancer Control \[UICC\] stage IIIb/IV; non-resectable NSCLC)
* From 07/2023: histologically confirmed NSCLC stage Ib, II, III (UICC)
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Charite University, Berlin, Germany
OTHER
Helios Klinikum Emil von Behring
UNKNOWN
Vivantes Hospital Berlin Neukölln
UNKNOWN
University Hospital Carl Gustav Carus
OTHER
Heinrich-Heine University, Duesseldorf
OTHER
University Hospital Erlangen
OTHER
University Hospital, Essen
OTHER
Goethe University
OTHER
University Hospital Freiburg
OTHER
University Hospital Giessen and Marburg
UNKNOWN
University Hospital Halle (Saale)
UNKNOWN
Universitätsklinikum Hamburg-Eppendorf
OTHER
University Hospital Heidelberg
OTHER
Klinikum Hanover-Siloah Hospital
OTHER
University Hospital, Bonn
OTHER
University Hospital Schleswig-Holstein
OTHER
Johannes Gutenberg University Mainz
OTHER
University Hospital Munich (LMU)
UNKNOWN
University Hospital rechts der Isar Munich (TUM)
UNKNOWN
Pius-Hospital Oldenburg
OTHER
University Hospital Regensburg
OTHER
University Hospital Tuebingen
OTHER
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
OTHER
University Hospital Ulm
OTHER
Wuerzburg University Hospital
OTHER
University Hospital of Cologne
OTHER
Prof. Dr. Juergen Wolf
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Dr. Juergen Wolf
Professor Dr. med., Spokesperson of the National Network Genomic Medicine Lung Cancer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Juergen Wolf, Prof. Dr.
Role: STUDY_CHAIR
University of Cologne
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Cologne
Cologne, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Janning M, Suptitz J, Albers-Leischner C, Delpy P, Tufman A, Velthaus-Rusik JL, Reck M, Jung A, Kauffmann-Guerrero D, Bonzheim I, Brandlein S, Hummel HD, Wiesweg M, Schildhaus HU, Stratmann JA, Sebastian M, Alt J, Buth J, Esposito I, Berger J, Togel L, Saalfeld FC, Wermke M, Merkelbach-Bruse S, Hillmer AM, Klauschen F, Bokemeyer C, Buettner R, Wolf J, Loges S; National Network Genomic Medicine Lung Cancer (nNGM). Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM). Ann Oncol. 2022 Jun;33(6):602-615. doi: 10.1016/j.annonc.2022.02.225. Epub 2022 Mar 6.
Saleh MM, Scheffler M, Merkelbach-Bruse S, Scheel AH, Ulmer B, Wolf J, Buettner R. Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC. J Thorac Oncol. 2022 Jan;17(1):76-88. doi: 10.1016/j.jtho.2021.08.764. Epub 2021 Sep 30.
Saalfeld FC, Wenzel C, Christopoulos P, Merkelbach-Bruse S, Reissig TM, Lassmann S, Thiel S, Stratmann JA, Marienfeld R, Berger J, Desuki A, Velthaus JL, Kauffmann-Guerrero D, Stenzinger A, Michels S, Herold T, Kramer M, Herold S, Tufman A, Loges S, Alt J, Joosten M, Schmidtke-Schrezenmeier G, Sebastian M, Stephan-Falkenau S, Waller CF, Wiesweg M, Wolf J, Thomas M, Aust DE, Wermke M; National Network Genomic Medicine Lung Cancer (nNGM). Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations. J Thorac Oncol. 2021 Nov;16(11):1952-1958. doi: 10.1016/j.jtho.2021.06.025. Epub 2021 Jul 8.
Related Links
Access external resources that provide additional context or updates about the study.
Website of the national Network Genomic Medicine Lung Cancer, Germany
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NNGM0418
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.